NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential ...

NEW YORK CITY, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

GSK PLC closed 26.98% short of its 52-week high of £18.24, which the company reached on May 16th.

GSK PLC closed 30.68% below its 52-week high of £18.24, which the company achieved on May 16th.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc (“GSK” or “the Company”) (NYSE: GSK) for violations of ...

LOS ANGELES, April 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc ("GSK" or "the Company ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier (BBB) penetrating ...